Insights from a Matching-Adjusted Indirect Comparison of Zanubrutinib and Venetoclax plus Obinutuzumab
Intended for Physicians
Chapter 1
Navigating First-Line CLL Treatment Choices: Clinical Considerations Between Continuous Zanubrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab
Chapter 2
Rationale and Methodology for Conducting a Matching-Adjusted Indirect Comparison of Zanubrutinib vs Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
Chapter 3
Indirect Comparison of the Efficacy and Safety of Zanubrutinib vs Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
Chapter 4
Clinical Implications of an Indirect Comparison of Zanubrutinib vs Venetoclax Plus Obinutuzumab to Inform Treatment Sequencing and Guide Decision-Making in Frontline CLL
Topics:
Chapters
(Subsequent chapters are available upon completion of the prior chapter)
Coming up next in 0:00
Watched
Placeholder
Navigating First-Line CLL Treatment Choices: Clinical Considerations Between Continuous Zanubrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab
Chapter 1 | 6m 36s
Coming up next in 01:05
Watched
Placeholder
Rationale and Methodology for Conducting a Matching-Adjusted Indirect Comparison of Zanubrutinib vs Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
Chapter 2 | 5m 37s
Coming up next in 00:00
Watched
Placeholder
Indirect Comparison of the Efficacy and Safety of Zanubrutinib vs Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
Chapter 3 | 4m 37s
Coming up next in 00:00
Watched
Placeholder
Clinical Implications of an Indirect Comparison of Zanubrutinib vs Venetoclax Plus Obinutuzumab to Inform Treatment Sequencing and Guide Decision-Making in Frontline CLL
Chapter 4 | 5m 17s
Program Objectives
Discuss the study design of the matching-adjusted indirect comparison (MAIC) analysis from Munir et al.
Summarize efficacy and safety outcomes between treatment-naïve CLL patients treated with zanubrutinib in the SEQUOIA trial and those treated with venetoclax plus obinutuzumab in the CLL14 trial.
Discuss the clinical implications and limitations of MAIC findings when comparing continuous vs fixed-duration treatment strategies in treatment-naïve CLL
Clinical Perspectives Presented by:
Associate Professor of Clinical Medicine Tulane Cancer Center Member – Translational Oncology Research Program
This site is intended for US Healthcare Professionals only. Use of and access to this site are subject to the Terms of Use and Privacy Policy. The information contained herein is provided for educational purposes only. All decisions regarding patient care must be made by a healthcare provider considering the unique characteristics of the patient. OncLive and Targeted Oncology are owned by MJH Life Sciences.